Next Article in Journal
Controlled Synthesis of Monodisperse Hexagonal NaYF4:Yb/Er Nanocrystals with Ultrasmall Size and Enhanced Upconversion Luminescence
Next Article in Special Issue
Exogenous Melatonin Alleviates Cold Stress by Promoting Antioxidant Defense and Redox Homeostasis in Camellia sinensis L.
Previous Article in Journal
An Interface for Biomedical Big Data Processing on the Tianhe-2 Supercomputer
Previous Article in Special Issue
Melatonin Improves the Quality of Inferior Bovine Oocytes and Promoted Their Subsequent IVF Embryo Development: Mechanisms and Results
Open AccessFeature PaperArticle

Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates

1
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, Italy
2
Department of Molecular and Developmental Medicine, University of Siena, Viale Bracci, 53100 Siena, Italy
3
Department of Human Pathology in Adult and Developmental Age “Gaetano Barresi”—Neonatal Intensive Care Unit, University of Messina, Via Consolare Valeria 1, 98125 Gazzi Messina, Italy
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Molecules 2017, 22(12), 2115; https://doi.org/10.3390/molecules22122115
Received: 9 November 2017 / Revised: 29 November 2017 / Accepted: 29 November 2017 / Published: 1 December 2017
Melatonin possesses potential efficacy in perinatal brain injuries, and has been proposed as adjunctive pharmacological therapy in combination with hypothermia in the clinical setting. However, the pharmacokinetics of melatonin in preterm and term newborns is still unknown. The aim of this study was to analyze the pharmacokinetics of melatonin after intragastric administration in preterm infants. Preterm newborns were enrolled 24–72 h after birth, and randomly assigned to three groups receiving a single bolus of 0.5 mg·kg−1 melatonin, or 3 boluses of 1 or 5 mg·kg−1 of melatonin at 24-h intervals. Blood samples were collected before and at selective times after melatonin administration. The half-life of melatonin in plasma ranged from 7.98 to 10.94 h, and the area under the curve (AUC) from 10.48 to 118.17 µg·mL−1·h−1. Our results indicate a different pharmacokinetic profile in premature newborns, compared to adults and experimental animals. The high peak plasma concentrations and the long half-life indicate that in the neonatal clinical setting, it is possible to obtain and maintain high serum concentrations using a single administration of melatonin repeated every 12/24 h. View Full-Text
Keywords: melatonin; pharmacokinetics; preterm infants; immaturity; neuroprotective agents melatonin; pharmacokinetics; preterm infants; immaturity; neuroprotective agents
Show Figures

Figure 1

MDPI and ACS Style

Carloni, S.; Proietti, F.; Rocchi, M.; Longini, M.; Marseglia, L.; D’Angelo, G.; Balduini, W.; Gitto, E.; Buonocore, G. Melatonin Pharmacokinetics Following Oral Administration in Preterm Neonates. Molecules 2017, 22, 2115.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop